<document page-count="5">
<page number="1">
<table data-filename="01.EVOLUTION OF IMMUNOBIOLOGICAL CHANGES.pdf" data-page="1" data-table="1"><tr><td colspan="2">Archives of the Balkan Medical Union</td><td>vol. 54, no. 2, pp. 222-226</td></tr><tr><td colspan="2">Copyright © 2019 Balkan Medical Union</td><td>June 2019</td></tr><tr><td></td><td></td><td>ORIGINAL PAPER</td></tr><tr><td colspan="3">EVOLUTION OF IMMUNOBIOLOGICAL CHANGES AND</td></tr><tr><td colspan="3">THEIR SIGNIFICANCE FOR THE TREATMENT OF PATIENTS</td></tr><tr><td colspan="3">WITH NON-HODGKIN’S LYMPHOMA</td></tr><tr><td colspan="2">Aliona NICORICI 1</td><td></td></tr><tr><td style="text-align: right">1</td><td colspan="2">Public Health Institution Institute of Oncology, Chisinau, Republic of Moldova</td></tr><tr><td></td><td></td><td>Received 29 Mar 2019, Accepted 15 May 2019</td></tr><tr><td></td><td></td><td>https://doi.org/10.31688/ABMU.2019.54.2.01</td></tr><tr><td>A BSTRACT</td><td></td><td>R ÉSUMÉ</td></tr><tr><td>Introduction.</td><td>Non-Hodgkin’s lymphoma (NHL)</td><td>Evolution des modifications immunobiologiques et</td></tr><tr><td colspan="2">shows clonal and uncontrolled proliferation of imma-</td><td>leur importance dans le traitement de patients at-</td></tr><tr><td colspan="2">ture lymphoid precursors.</td><td>teints de lymphome non-Hodgkinien</td></tr><tr><td colspan="2">The aim of the study. Dynamic analysis of immuno-</td><td></td></tr><tr><td colspan="2">biological and immunophenotypic parameters in the</td><td>Introduction. Le lymphome non-Hodgkinien (LNH)</td></tr><tr><td colspan="2">treatment of patients with NHL, and recognition of</td><td>montre une prolifération clonale et incontrôlée de pré-</td></tr><tr><td colspan="2">immunological remissions.</td><td>curseurs lymphoïdes immatures.</td></tr><tr><td colspan="2">Material and methods.The retrospective study</td><td>Le but de l’étude.Analyse dynamique des para-</td></tr><tr><td colspan="2">group consisted of 122 patients, admitted between</td><td>mètres immunobiologiques et immunophénotypiques</td></tr><tr><td colspan="2">2012 and 2015 in the Hematology Clinic of the</td><td>dans le traitement des patients atteints de LNH et re-</td></tr><tr><td colspan="2">Republic of Moldova Oncology Institute, with a mor-</td><td>connaissance des rémissions immunologiques.</td></tr><tr><td colspan="2">phologically confirmed diagnosis of NHL. We assessed</td><td>Matériel et méthodes. Le groupe d’étude rétrospec-</td></tr><tr><td colspan="2">the predominant phenotypic line by indirect immuno-</td><td>tif était composé de 122 patients, admis entre 2012 et</td></tr><tr><td colspan="2">phenotyping and total concentration of immunoglob-</td><td>2015 à la clinique d’hématologie de l’Institut d’Onco-</td></tr><tr><td colspan="2">ulin classes (A, M, G) according to treatment regimens</td><td>logie de la République de Moldova, avec un diagnos-</td></tr><tr><td colspan="2">applied to NHL patients.</td><td>tic de LNH confirmé par la morphologie. Nous avons</td></tr><tr><td colspan="2">Results.119 patients showed CD19 antigen and</td><td>évalué la lignée phénotypique prédominante par im-</td></tr><tr><td colspan="2">CD20 increased expression of cell line B phenotype</td><td>munophénotypage indirect et concentration totale des</td></tr><tr><td colspan="2">(84.4%); only 3 patients in the study showed increased</td><td>classes d’immunoglobulines (A, M, G) en fonction des</td></tr><tr><td colspan="2">CD3, CD5, resulting in the predominant T-cell phe-</td><td>schémas thérapeutiques appliqués aux patients présen-</td></tr><tr><td colspan="2">notype line. NHL patients with both aggressive and</td><td>tant un LNH diagnostiqué.</td></tr><tr><td colspan="2">non-aggressive primary variants after 3 cycles and 6 cy-</td><td>Résultats. 119 patients ont présenté l’expression ac-</td></tr><tr><td colspan="2">cles presented a significant decrease in immunoglobu-</td><td>crue de l’antigène CD19 et CD20 du phénotype de la</td></tr><tr><td colspan="2">lin A, M, and G indices, on average of 7.3±0.2(mg/ml)</td><td>lignée B (84,4%); seuls 3 patients de l’étude ont pré-</td></tr><tr><td colspan="2">(p&lt;0.05), while the immunological indices of patients</td><td>senté une augmentation de CD3, CD5, entraînant la</td></tr><tr><td colspan="2">treated with the polychemotherapy (PTCH) scheme 2</td><td>lignée de phénotype prédominant des cellules T avec</td></tr><tr><td colspan="2">reported statistically significant minimal decreases (p</td><td>un poids de 2,4%. Les patients LNH avec des variantes</td></tr><tr><td>Address for correspondence:</td><td colspan="2">Aliona NICORICI</td></tr><tr><td colspan="3">Public Health Institution Institute of Oncology, Chisinau, Republic of Moldova</td></tr><tr><td colspan="3">Email: alionanicorici@yahoo.com; Phone 068599004</td></tr></table></page>
<page number="2">
<table data-filename="01.EVOLUTION OF IMMUNOBIOLOGICAL CHANGES.pdf" data-page="2" data-table="1"><tr><td></td><td></td><td>Archives of the Balkan Medical Union</td></tr><tr><td>&lt;0.05), setting an incomplete immunological remis-</td><td colspan="2">primaires agressives et non agressives après 3 cycles et</td></tr><tr><td>sion.</td><td colspan="2">6 cycles dans tous les groupes de traitement assignés</td></tr><tr><td>Conclusions.Due to the information obtained by</td><td colspan="2">aux schémas thérapeutiques ont noté une diminution</td></tr><tr><td>periodic monitoring of patients with NHL following</td><td colspan="2">significative des indices d’immunoglobuline A, M et</td></tr><tr><td>the termination of conventional clinical protocols, it</td><td colspan="2">G en moyenne de 7,3 ± 0,2(mg/ml) (p&lt;0,05), alors que</td></tr><tr><td>was possible to reveal the immunological and immuno-</td><td colspan="2">les indices immunologiques des patients traités avec</td></tr><tr><td>phenotypic features of the disease, for the detection of</td><td colspan="2">le schéma de polychimiothérapie (PCHT) 2 faisaient</td></tr><tr><td>early and late recurrences, late side effects, occurrence</td><td colspan="2">état de diminutions minimales statistiquement signi-</td></tr><tr><td>of the second malignancy, with the evaluation of the</td><td colspan="2">ficatives (p&lt;0,05), ce qui établissait une rémission im-</td></tr><tr><td>immunological and immunophenotypic remission and</td><td colspan="2">munologique incomplète.</td></tr><tr><td>identification of specific molecular targets for subse-</td><td colspan="2">Conclusions. Grâce à la recherche sur le suivi pério-</td></tr><tr><td>quent targeted therapy.</td><td colspan="2">dique des patients atteints de LNH à la suite de l’arrêt</td></tr><tr><td></td><td colspan="2">des protocoles cliniques conventionnels, il a été pos-</td></tr><tr><td>Keywords:polychemotherapy, non-Hodgkin’s lym-</td><td colspan="2">sible de révéler les caractéristiques immunologiques et</td></tr><tr><td>phoma, target treatment, monoclonal antibodies, im-</td><td colspan="2">immunophénotypiques de la maladie lors de la détec-</td></tr><tr><td>munoglobulins.</td><td colspan="2">tion de récidives précoces et tardives, d’effets secon-</td></tr><tr><td></td><td colspan="2">daires tardifs, de la survenue d’un deuxième cancer</td></tr><tr><td>List of abbreviations:</td><td colspan="2">avec l’évaluation de la rémission immunologique et</td></tr><tr><td>NHL – Non-Hodgkin’s lymphoma</td><td colspan="2">immunophénotypique, pour déclencher l’identifica-</td></tr><tr><td>mAb – monoclonal antibodies</td><td colspan="2">tion de cibles moléculaires spécifiques, en vue d’une</td></tr><tr><td>PCHT – polychemotherapy</td><td colspan="2">thérapie ciblée ultérieure.</td></tr><tr><td>Ig – immunoglobulins</td><td colspan="2">Mots-clés: polychimiothérapie, lymphome non-Hodg-</td></tr><tr><td></td><td colspan="2">kinien, traitement ciblé, anticorps monoclonaux, im-</td></tr><tr><td></td><td colspan="2">munoglobulines.</td></tr><tr><td></td><td colspan="2">Liste des abréviations:</td></tr><tr><td></td><td colspan="2">LNH – lymphome non-Hodgkinien</td></tr><tr><td></td><td colspan="2">AcMo – anticorps monoclonaux</td></tr><tr><td></td><td colspan="2">PCHT – polychimiothérapie</td></tr><tr><td></td><td colspan="2">Ig – immunoglobulines</td></tr><tr><td>I NTRODUCTION</td><td colspan="2">help in the staging and detection of residual minimal</td></tr><tr><td></td><td>disease7-9.</td><td></td></tr><tr><td>Non-Hodgkin’s lymphoma (NHL) represents the</td><td></td><td>In addition to its use in diagnosis, immunobi-</td></tr><tr><td>clonal and uncontrolled proliferation of immature</td><td colspan="2">ological research can serve as a starting point in the</td></tr><tr><td>lymphoid precursors, which lose their differentiation</td><td colspan="2">selection of individualized therapy, as well as in the</td></tr><tr><td>capacity and cause lymphoid organ hypertrophy1,2 .</td><td colspan="2">determination of the moment of occurrence and in-</td></tr><tr><td>Immunological tests are currently very important</td><td colspan="2">stallation of immunological and immunophenotypic</td></tr><tr><td>for diagnosis, completing the morphological study,</td><td colspan="2">remissions10-12 .</td></tr><tr><td>in the analysis of malignant lymphoproliferative dis-</td><td></td><td></td></tr><tr><td>eases 3,4 . In addition, the results of the immunopheno-</td><td>THE</td><td>AIM OF THE STUDY</td></tr><tr><td>typic assays can be used to identify the expression of</td><td></td><td></td></tr><tr><td>targets for antibody therapy and to provide addition-</td><td></td><td>Dynamic analysis of expression of immunobi-</td></tr><tr><td>al prognostic information. Also, following therapy,</td><td colspan="2">ological and immunophenotypic parameters in NHL</td></tr><tr><td></td><td colspan="2">patients, before and after treatment, to demonstrate</td></tr><tr><td>immunophenotyping may be a method of assessing</td><td colspan="2">and argue the scientific value of predictive factors in</td></tr><tr><td>residual minimal disease. Neoplastic mature B lym-</td><td colspan="2">improving the long-term survival rate and the recog-</td></tr><tr><td>phoid cells can be distinguished from normal cells</td><td colspan="2">nition of immunological and immunophenotypic re-</td></tr><tr><td>by identifying two major types of phenotypic abnor-</td><td colspan="2">missions in the choice of treatment methods.</td></tr><tr><td>malities – the Ig light chain class restriction and the</td><td></td><td></td></tr><tr><td>aberrant expression of antigens 4-6 .</td><td>M ATERIAL</td><td>AND METHODS</td></tr><tr><td>Immunophenotyping is recommended as one</td><td></td><td></td></tr><tr><td>of the ideal strategies for accurately detecting the</td><td></td><td>The retrospective study group consisted of</td></tr><tr><td>phenotype of neoplastic proliferative lesions and can</td><td colspan="2">122 patients, admitted between 2012 and 2015 in</td></tr><tr><td></td><td></td><td>June 2019 / 223</td></tr></table></page>
<page number="3">
<table data-filename="01.EVOLUTION OF IMMUNOBIOLOGICAL CHANGES.pdf" data-page="3" data-table="1"><tr><td colspan="17">Evolution of immunobiological changes and their significance for the treatment of patients... – NICORICI et al</td></tr><tr><td colspan="8">the Hematology Clinic of the Republic of Moldova</td><td colspan="9">Indirect immunophenotypic investigation was</td></tr><tr><td colspan="8">Oncology Institute, Chisinau, with a morphologically</td><td colspan="9">performed in several steps: collection specimens for</td></tr><tr><td colspan="8">confirmed diagnosis of NHL. All the patients signed</td><td colspan="9">research, lymphocyte ring separation step, lympho-</td></tr><tr><td colspan="8">an informed consent. The average age of the patients</td><td colspan="9">cyte dilution step, approximate dissolution step, mAb</td></tr><tr><td colspan="8">was 56.5 years; the study group included 58 men and</td><td colspan="9">lymphocyte tagging step, mAb labeled lymphocyte</td></tr><tr><td colspan="8">64 women.</td><td colspan="9">dilution step, fluorescence labeling in lymphocyte</td></tr><tr><td colspan="8">The methods of direct and indirect observation</td><td colspan="9">stages, visualization of malignant lymphocytes in a</td></tr><tr><td colspan="8">have been used in peripheral blood research since</td><td colspan="9">dark field and interpretation of the results.</td></tr><tr><td colspan="8">the onset of the disease, following the application</td><td colspan="9">According to the research methodology, immu-</td></tr><tr><td colspan="8">of specific therapy with intervals of 3 and 6 specific</td><td colspan="9">nological evidence has been investigated in patients</td></tr><tr><td colspan="8">treatment cycles polychemotherapy, with the evalua-</td><td colspan="9">with NHL, grouped according to treatment regimes</td></tr><tr><td colspan="8">tion of humoral homeostasis indices, the assessment</td><td colspan="9">applied and morphological types in three study</td></tr><tr><td colspan="8">of the lymphoma phenotype by labeling monoclonal</td><td colspan="9">groups, on both cell line B and cell line T (Table 1).</td></tr><tr><td colspan="8">antibody (mAb) lymphocytes using luminescent mi-</td><td colspan="9"></td></tr><tr><td colspan="8">croscopy in the dark field, comparing them for a de-</td><td colspan="9">R ESULTS</td></tr><tr><td colspan="8">ductive analysis.</td><td colspan="9"></td></tr><tr><td colspan="8">Through the validated data at repeated hospi-</td><td colspan="9">Of the 122 histopathologically diagnosed NHL</td></tr><tr><td colspan="8">talizations, we recorded the influence of the response</td><td colspan="9">patients enrolled in the study and examined by the</td></tr><tr><td colspan="8">to the applied treatment, relapses and refractory</td><td colspan="9">indirect immunophenotyping method of peripheral</td></tr><tr><td colspan="8">post-treatment complications.</td><td colspan="9">blood research by labeling lymphocytes with mAb,</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="10">Table 1. Distribution of patients according to PCHT treatment.</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">NHL subtype</td><td></td><td></td><td colspan="5">NHL patients included in the study</td><td colspan="3">PCHT treatment</td><td></td><td colspan="2">Treatment regimens</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Cyclofosfan</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Doxorubicin</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">56</td><td></td><td></td><td colspan="3">1. CHOP</td><td></td><td colspan="2">Oncocin (vincristine)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Prednisolone</td><td></td></tr><tr><td colspan="5">Aggressive LNH (lympho-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>blastic)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="4">Rituximab (antiCD20)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="5">12 (determined cell line by immuno-</td><td></td><td></td><td></td><td></td><td colspan="2">Cyclofosfan</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">2. R – CHOP</td><td></td><td colspan="2">Doxorubicin</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">histochemistry biopsy)</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Oncocin (vincristine)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Prednisolone</td><td></td></tr><tr><td colspan="5">NHL<br/>nonaggressive<br/>(indolent, pro-inflammatory)</td><td></td><td></td><td style="text-align: right">54</td><td></td><td></td><td colspan="3">3. CVLP</td><td></td><td colspan="2">Cyclofosfan<br/>Vinblastine<br/>Leukeran<br/>Prednisolone</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="11">Table 2. 100% malignant cells (B lymphocyte cell line phenotype).</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>CD 20</td><td></td><td></td><td></td><td></td><td></td><td></td><td>CD 19</td><td></td><td></td><td></td></tr><tr><td colspan="2">No.patients</td><td style="text-align: right">%</td><td></td><td>abs.</td><td></td><td></td><td style="text-align: right">%</td><td></td><td>ci</td><td></td><td>abs.</td><td></td><td></td><td style="text-align: right">%</td><td></td><td>ci</td></tr><tr><td></td><td></td><td></td><td>min</td><td>med</td><td>max</td><td>min</td><td>med</td><td>max</td><td style="text-align: right">25.4±</td><td>min</td><td>med</td><td>max</td><td>min</td><td>med</td><td>max</td><td style="text-align: right">19.8±</td></tr><tr><td style="text-align: right" colspan="2">119</td><td style="text-align: right">100</td><td style="text-align: right">13</td><td style="text-align: right">42</td><td style="text-align: right">98</td><td style="text-align: right">11.2%</td><td style="text-align: right">36.2%</td><td style="text-align: right">84.4%</td><td style="text-align: right">0.7</td><td style="text-align: right">9</td><td style="text-align: right">32</td><td style="text-align: right">75</td><td style="text-align: right">7.75%</td><td style="text-align: right">27.58%</td><td style="text-align: right">64.67%</td><td style="text-align: right">2.3</td></tr><tr><td></td><td></td><td></td><td colspan="12">Table 3. Total IgA, IgM, IgG Assay PCHT Study Group Scheme N o 1.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="6">Aggressive NHL (Lymphoblastic)13, 14, 16</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Primary<br/>M(mg/mL)</td><td></td><td colspan="6">M(mg/mL)± after 3 cycles of PCHT</td><td colspan="5">M(mg/mL)± after 6 cycles of PCHT</td></tr><tr><td colspan="2">IgA</td><td colspan="4">1.4±0.1 mg/mL</td><td></td><td colspan="3">1.1±0.02 mg/mL</td><td></td><td></td><td></td><td colspan="3">1.0±0.01 mg/mL</td><td></td></tr><tr><td colspan="2">IgM</td><td colspan="4">1.6±0.05 mg/mL</td><td></td><td colspan="3">1.4±0.08 mg/mL</td><td></td><td></td><td></td><td colspan="3">1.2±0.06 mg/mL</td><td></td></tr><tr><td colspan="2">IgG</td><td colspan="4">17.5±0.2 mg/mL</td><td></td><td colspan="3">16.8±0.1 mg/mL</td><td></td><td></td><td></td><td colspan="3">15.2±0.1 mg/mL</td><td></td></tr><tr><td>p</td><td></td><td></td><td style="text-align: right" colspan="2">&lt;0.05</td><td></td><td></td><td></td><td style="text-align: right" colspan="2">&lt;0.05</td><td></td><td></td><td></td><td></td><td style="text-align: right" colspan="2">&lt;0.01</td><td></td></tr><tr><td>t</td><td></td><td></td><td style="text-align: right" colspan="2">2.84</td><td></td><td></td><td></td><td style="text-align: right" colspan="2">0.98</td><td></td><td></td><td></td><td></td><td style="text-align: right">1.82</td><td></td><td></td></tr><tr><td style="text-align: right">224</td><td style="text-align: right">/</td><td colspan="2">vol. 54, no. 2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></page>
<page number="4">
<table data-filename="01.EVOLUTION OF IMMUNOBIOLOGICAL CHANGES.pdf" data-page="4" data-table="1"><tr><td colspan="5">Archives of the Balkan Medical Union</td></tr><tr><td colspan="5">Table 4. Results of Ig A, IgM, and IgG according to PCHT treatment scheme N o 3 in repeated cycling periods</td></tr><tr><td></td><td></td><td colspan="2">for non-aggressive NHL.</td><td></td></tr><tr><td></td><td></td><td colspan="2">Indolent NHL (prolymphocyte)13, 14, 16</td><td></td></tr><tr><td></td><td>Primary</td><td colspan="2"></td><td></td></tr><tr><td></td><td></td><td colspan="2">M(mg/mL)± after 3 cycles of PCHT</td><td>M(mg/ml)± after 6 cycles of PCHT</td></tr><tr><td></td><td>M(mg/mL)</td><td colspan="2"></td><td></td></tr><tr><td>IgA</td><td>1.4±0.08 mg/mL</td><td colspan="2">1.2±0.04 mg/mL</td><td>1.1±0.02 mg/mL</td></tr><tr><td>IgM</td><td>1.6±0.05 mg/mL</td><td colspan="2">1.4±0.08 mg/mL</td><td>1.2±0.01 mg/mL</td></tr><tr><td>IgG</td><td>19.1±0.2 mg/mL</td><td colspan="2">18.8±0.2 mg/mL</td><td>15.6±0.03 mg/mL</td></tr><tr><td>p</td><td style="text-align: right">&lt; 0.05</td><td style="text-align: right" colspan="2">&lt; 0.05</td><td style="text-align: right">&lt; 0.05</td></tr><tr><td>t</td><td style="text-align: right">2.34</td><td style="text-align: right" colspan="2">1.22</td><td style="text-align: right">1.96</td></tr><tr><td colspan="5">Table 5. Results of IgA, IgM, IgG according to PCHT treatment scheme No 2 in repeated cycles for NHL B – cell.</td></tr><tr><td></td><td></td><td>NHL B – cell</td><td></td><td></td></tr><tr><td></td><td>Primary</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">M(mg/mL)± after 3 cycles of PCHT</td><td>M(mg/mL)± after 6 cycles of PCHT</td></tr><tr><td></td><td>M (mg/mL)</td><td></td><td></td><td></td></tr><tr><td>IgA</td><td>2.5±0.02 mg/mL</td><td>1.7±0.02 mg/mL</td><td></td><td>1.9±0.01 mg/mL</td></tr><tr><td>IgM</td><td>1.6±0.01 mg/mL</td><td>1.4±0.04 mg/mL</td><td></td><td>1.4±0.03 mg/mL</td></tr><tr><td>IgG</td><td>12.3±0.03 mg/mL</td><td>18.8±0.2 mg/mL</td><td></td><td>16.7±1.3 mg/mL</td></tr><tr><td>p</td><td style="text-align: right">&lt;0.05</td><td style="text-align: right">&lt;0.01</td><td></td><td style="text-align: right">&lt;0.05</td></tr><tr><td>t</td><td style="text-align: right">2.36</td><td style="text-align: right">1.08</td><td></td><td style="text-align: right">1.98</td></tr><tr><td colspan="3">119 patients showed increased affinity for the CD19,</td><td colspan="2">In our study, the T-cell NHL was rare, with a</td></tr><tr><td colspan="3">CD20 antigen, expressing the cell line B phenotype</td><td colspan="2">frequency of 2.4% versus 10% compared to literature</td></tr><tr><td>(Table 2).</td><td></td><td></td><td>data 9, 14, 17.</td><td></td></tr><tr><td colspan="3">As a result of the immunophenotypic investiga-</td><td colspan="2">Table 3 revealed the dynamics of IgA, IgM and</td></tr><tr><td colspan="3">tion of the same group of NHL patients by labeling</td><td colspan="2">IgG indices during PCHT in 56 patients treated ac-</td></tr><tr><td colspan="3">lymphocytes with CD3 and CD5 monoclonal anti-</td><td colspan="2">cording to protocol treatment scheme 1 and with re-</td></tr><tr><td colspan="3">bodies, we determined that only 3 patients had lym-</td><td colspan="2">peated control of their values after 3 and 6 PCHT</td></tr><tr><td colspan="2">phocyte T phenotype.</td><td></td><td colspan="2">cycles. The results showed a significant decrease in</td></tr><tr><td colspan="3">Thus, the total concentration of immunoglobu-</td><td colspan="2">all immunoglobulin indices, both primary and in the</td></tr><tr><td colspan="3">lins (Ig): IgA, IgM and IgG in the group of patients</td><td colspan="2">dynamics after the 3rd and 6 th cure of PCHT.</td></tr><tr><td colspan="3">receiving PCHT according to Scheme 1 follows a</td><td colspan="2">In patients treated with the No 1 and 3 schemes,</td></tr><tr><td colspan="2">downward trend (Table 3).</td><td></td><td colspan="2">significant decreases of the IgA, IgM, IgG classes,</td></tr><tr><td colspan="3">54 NHL patients had indolent morphological</td><td colspan="2">both primary and after 3 and 6 cycles of PCHT, have</td></tr><tr><td colspan="3">subtypes treated with the PCHT treatment scheme</td><td colspan="2">been observed. Thus, primary IgA level was 2.5±0.02</td></tr><tr><td colspan="3">3 and presented a relatively insignificant decrease in</td><td colspan="2">mg/mlL, after 3 courses it was 1.7±0.02 mg/mlL and</td></tr><tr><td colspan="3">the indices of the Ig A, IgM and IgG (Table 4).</td><td colspan="2">after 6 courses it was 1.9±0.01 mg/mL, primary IgM</td></tr><tr><td colspan="3">In the 12 patients with B-cell LNH (confirmed by</td><td colspan="2">was 1.6±0.01 mg/mL, after 3 cures it was 1.4±0.04</td></tr><tr><td colspan="3">immunohistochemical examination) who received the</td><td colspan="2">mg/mL, after 6 cures 1.4±0.03 mg/mL. Primary IgG</td></tr><tr><td colspan="3">PCHT scheme 2 (R-CHOP), an insignificant reduc-</td><td colspan="2">was 12.3±0.03 mg/mL, after 3 courses it was 18.8±0.2</td></tr><tr><td colspan="3">tion in the immune response was observed (Table 5).</td><td colspan="2">mg/mL, after 6 courses 16.7±1.3 mg/mL (Table 4).</td></tr><tr><td></td><td></td><td></td><td colspan="2">The results obtained show that the patients in</td></tr><tr><td colspan="2">D ISCUSSION</td><td></td><td colspan="2">the PCHT mAb CD20 (MabThera) PCHT group</td></tr><tr><td></td><td></td><td></td><td colspan="2">(Table 5) had an attenuation of the statistically sig-</td></tr><tr><td colspan="3">Our study shows that B lymphoid cells have a</td><td colspan="2">nificant immune response, where p 0.05 established</td></tr><tr><td colspan="3">progressive proliferation tendency, which justifies</td><td colspan="2">the occurrence of an incomplete immunological re-</td></tr><tr><td colspan="3">the inclusion in the treatment of NHL of specific</td><td>mission.</td><td></td></tr><tr><td colspan="3">monoclonal antibodies as targeted therapy. The pro-</td><td></td><td></td></tr><tr><td colspan="3">portion of B cells phenotype, encountered in 84.4%</td><td>C ONCLUSIONS</td><td></td></tr><tr><td colspan="3">of patients enrolled in the study, did not differ sig-</td><td></td><td></td></tr><tr><td colspan="3">nificantly from the literature (over 90% of cases with</td><td colspan="2"> Indirect immunophenotypic complement tests,</td></tr><tr><td>B cells)11,12 .</td><td></td><td></td><td colspan="2">that allowed us to detect B cell line of NHL by</td></tr><tr><td></td><td></td><td></td><td></td><td>June 2019 / 225</td></tr></table></page>
<page number="5">
<table data-filename="01.EVOLUTION OF IMMUNOBIOLOGICAL CHANGES.pdf" data-page="5" data-table="1"><tr><td colspan="4">Evolution of immunobiological changes and their significance for the treatment of patients... – NICORICI et al</td></tr><tr><td colspan="2">labeling lymphocytes with mAb CD20, CD19,</td><td style="text-align: right">4.</td><td>Calvo K, Mc CoyCS, Stetler-Stevenson M. Flow cytometry</td></tr><tr><td colspan="2">revealed a significant number of malignant cells,</td><td></td><td>immunophenotyping of hematolymphoid neoplasia. Methods</td></tr><tr><td colspan="2">increased in 84.4% of the patients, proving that B</td><td></td><td>Mol Biol. 2011; 699: 295-316.</td></tr><tr><td></td><td></td><td style="text-align: right">5.</td><td>Greer J, Williams M. Non-Hodgkin Lymphoma in Adults.</td></tr><tr><td colspan="2">lymphocytes have a progressive proliferative evolu-</td><td></td><td>In: Greer J, Foerster J, Rodgers G, Pareskevas F, Glader B,</td></tr><tr><td colspan="2">tion, motivating inclusion in the treatment of mAb</td><td></td><td>eds. Wintrobe’s Clinical Hematology. 12th ed. Philadelphia,</td></tr><tr><td colspan="2">variants of NHL cells as target therapy.</td><td></td><td>PA: Lippincott Williams &amp; Wilkins, 2009:2144-2194.</td></tr><tr><td colspan="2"> CD3 and CD5 immunophenotypic examination in</td><td style="text-align: right">6.</td><td>Marcus R, Sweetenham JW, Williams ME. Lymphoma:</td></tr><tr><td colspan="2">NHL patients determined the predominant T-cell</td><td></td><td>pathology, diagnosis and treatment. Cambridge University</td></tr><tr><td colspan="2">phenotype in only 3 patients (2.4%), against 10%</td><td style="text-align: right">7.</td><td>Gaza E, Okada CY. Tumor cell lymphocyte-pulsed dendritic</td></tr><tr><td colspan="2">in the literature.</td><td></td><td>cells are more effective than TCR Id Protein vaccines for ac-</td></tr><tr><td colspan="2"> Due to the information obtained by periodic mo-</td><td></td><td>tive immunotherapy of T cell l Lymphoma. J Immunol 2009;</td></tr><tr><td colspan="2">nitoring of patients with NHL following the ter-</td><td></td><td>169; 5227-5235</td></tr><tr><td colspan="2">mination of conventional clinical protocols, it was</td><td style="text-align: right">8.</td><td>Rodriquez J, Caballero MD, Gutierrez A, et al. High-dose</td></tr><tr><td></td><td></td><td></td><td>chemotherapy and autologous stem cell transplantation in</td></tr><tr><td colspan="2">possible to reveal the immunological and immu-</td><td></td><td>peripheral T-cell lymphoma: the Gel-TAMO experience. Ann</td></tr><tr><td colspan="2">nophenotypic features of the disease, for the detec-</td><td></td><td>Oncol. 2003;14(12):1768-1775.</td></tr><tr><td colspan="2">tion of early and late recurrences, late side effects,</td><td style="text-align: right">9.</td><td>Moura IC, Lepelletier Y, Arnulf B, et al. A neutralizing mon-</td></tr><tr><td colspan="2">occurrence of the second malignancy, with the</td><td></td><td>oclonal antibody (mAb A24) directed against the transferrin</td></tr><tr><td colspan="2">evaluation of the immunological and immunophe-</td><td></td><td>receptor induces apoptosis of tumor T lymphocytes from</td></tr><tr><td></td><td></td><td></td><td>ATL patients. Blood. 2004; 103(5):1038-1845.</td></tr><tr><td colspan="2">notypic remission and identification of specific mo-</td><td colspan="2">10. Shustov AR, Savage KJ. Does high dose therapy and autolo-</td></tr><tr><td colspan="2">lecular targets for subsequent targeted therapy.</td><td></td><td>gous hematopoietic stem cell transplantation have a role</td></tr><tr><td></td><td></td><td></td><td>in the primary treatment of peripheral cell lymphomas?</td></tr><tr><td></td><td></td><td></td><td>Hematology Am Soc Hematol Educ Program; 2008:39-41.</td></tr><tr><td colspan="2">Compliance with Ethics Requirements:</td><td colspan="2">11. Kreitman RJ. Immunotoxins for targeted cancer therapy.</td></tr><tr><td></td><td>„The authors declare no conflict of interest regarding</td><td></td><td>AAPS J. 2006;8(3):E532-E551.</td></tr><tr><td></td><td></td><td colspan="2">12. Be| ne| M, Kaeda J. How and why minimal residual disease</td></tr><tr><td colspan="2">this article“</td><td></td><td>studies are necessary in leukemia: a review from WP10</td></tr><tr><td></td><td>„The authors declare that all the procedures and ex-</td><td></td><td>and WP12 of the European Leukemia Net. Haematologica.</td></tr><tr><td colspan="2">periments of this study respect the ethical standards in the</td><td></td><td>2009;94(8):1135-50.</td></tr><tr><td colspan="2">Helsinki Declaration of 1975, as revised in 2008(5), as</td><td colspan="2">13. Krivolapov Yu A, Leenman EE. Morphological diag-</td></tr><tr><td colspan="2">well as the national law. Informed consent was obtained</td><td></td><td>nostics by lymphoma. COSTA, 2006. https://epdf.</td></tr><tr><td></td><td></td><td></td><td>tips/-b0a5020784a056fc49db0f538fbd26d731335.html</td></tr><tr><td colspan="2">from all the patients included in the study“</td><td colspan="2">14. Mazurov VI, Krivalopov Yu A. Lymphoma classifica-</td></tr><tr><td></td><td>„No funding for this study“</td><td></td><td>tion, morphology, immunophenotype, molecular ge-</td></tr><tr><td></td><td></td><td></td><td>netics by non-Hodgkin’s lymphoma. Practical Oncology.</td></tr><tr><td></td><td></td><td></td><td>2004;3:169-175.</td></tr><tr><td></td><td></td><td colspan="2">15. Dzhazhilov AF. Non-Hodgkin’s lymphoma – the basis of</td></tr><tr><td colspan="2">R EFERENCES</td><td></td><td>classification and immunocytochemical diagnosis. Oncology.</td></tr><tr><td></td><td></td><td></td><td>2013;15(4):272.</td></tr><tr><td style="text-align: right">1.</td><td>Corcimaru I. Hematology. Kishinev, 2007, pg. 252-279.</td><td colspan="2">16. Swerdlow SH, Campo E, Harris NL, et al. WHO Classifi-</td></tr><tr><td style="text-align: right">2.</td><td>Buruiana S. Clinical, hematological and immunohistochem-</td><td></td><td>cation of tumors of hematopoietic and lymphoid tissues.</td></tr><tr><td></td><td>ical aspects of non-Hodgkin lymphocytes from lymphocytes.</td><td></td><td>IARC Press, Lyon, France. 4 th edition. 2008.</td></tr><tr><td></td><td>Infomed. 2016; 2(28):52-58.</td><td colspan="2">17. Catana A, Podia Igna C, Deac M. Clinical and histophe-</td></tr><tr><td style="text-align: right">3.</td><td>Kovalchuk LV, Gankovskaya LV, Meshkova R Ya. Clinical</td><td></td><td>notypic aspects in peripheral T-lymphoma on a group of</td></tr><tr><td></td><td>immunology and allergology with the basics of general im-</td><td></td><td>197 patients in Bucharest. Acta Medica Transilvanica. 2011;</td></tr><tr><td></td><td>munology: A textbook for universities. M. GEOTAR-Media,</td><td></td><td>2(3):97-100.</td></tr><tr><td></td><td style="text-align: right">2012.</td><td></td><td></td></tr><tr><td colspan="2">226 / vol. 54, no. 2</td><td></td><td></td></tr></table></page>
</document>
